Melanoma
Specialty Channel

Featured Article
True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
Researchers have proposed using 3 externally validated nomograms to predict local, regional, and distant recurrence in patients with thin primary cutaneous melanomas.
Study findings suggest that by including skin cancer content in cosmetology curricula, cosmetologists can be better screen their clients for suspicious lesions.
According to A. Hunter Shain, PhD, and colleagues, melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.
The FDA has approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a TFS twice as long as those given nivolumab alone.
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
Researchers propose using an externally validated nomogram to better select patients with T1 melanoma to undergo sentinel node biopsy.

News

Researchers have proposed using 3 externally validated nomograms to predict local, regional, and distant recurrence in patients with thin primary cutaneous melanomas.
Study findings suggest that by including skin cancer content in cosmetology curricula, cosmetologists can be better screen their clients for suspicious lesions.
According to A. Hunter Shain, PhD, and colleagues, melanoma can be predicted long before any suspicious moles are detected thanks to the identification of DNA mutations in individual skin cells.
The FDA has approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Interactive Features

True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.
True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.
True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.
True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.
Stay in the know.
OncNet Newsletter